Sare Verstockt1, Bram Verstockt1,2, Kathleen Machiels1, Maaike Vancamelbeke1, Marc Ferrante1,2, Isabelle Cleynen3, Gert De Hertogh4,5, Séverine Vermeire1,2. 1. Translational Research Center for GastroIntestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium. 2. University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium. 3. Laboratory for Complex Genetics, Department of Human Genetics, Leuven, Belgium. 4. Department of Morphology and Molecular Pathology, University Hospitals, Leuven, Belgium. 5. Department of Imaging and Pathology, Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.
Abstract
BACKGROUND: Oncostatin M (OSM) has been implicated in the pathogenesis of inflammatory bowel disease (IBD) and as a marker for nonresponsiveness to anti-tumor necrosis factor (TNF) therapy. We further unraveled the potential of OSM and related receptors as markers of diagnosis, prognosis, and therapy response in IBD. METHODS: We collected inflamed mucosal biopsies and serum from patients with Crohn disease (CD) and with ulcerative colitis: (1) newly diagnosed patients who were treatment-naïve, (2) patients initiating anti-TNF or (3) vedolizumab therapy, (4) postoperative patients with CD, and (5) multiple-affected families with IBD including unaffected first-degree relatives (FDRs). We measured the gene expression of mucosal OSM and its receptors OSMR/LIFR and co-receptor IL6ST, and the protein expression of serum OSM. Statistical significance was defined as P < 0.05. RESULTS: Newly diagnosed patients showed significantly increased mucosal OSM/OSMR compared with control patients, with the highest enrichment for OSM (fold change [FC] >17.9). Likewise, ileal OSM/OSMR were significantly upregulated in postoperative recurrent CD. Serum OSM was increased in newly diagnosed patients and postoperative patients with recurrent CD (FC ≥ 2.6). In families with IBD, higher serum levels were observed in FDRs than in control families (FC = 2.2). Furthermore, elevated colonic OSM/OSMR (but not serum OSM) were associated with the early need for biologic therapy (FC ≥ 1.9), and higher OSM was also predictive of primary nonresponse to both anti-TNF and vedolizumab therapy (FC ≥ 2.4). Immunohistochemistry highlighted mucosal OSM expression in macrophages. CONCLUSIONS: We found that OSM is a diagnostic biomarker in the tissue and serum not only of newly diagnosed patients with IBD and postoperative patients with recurrent CD but also of their FDRs. Higher colonic OSM levels are furthermore associated with poor prognosis and with primary nonresponse to biologic therapies. Therefore, OSM could guide clinical decision-making.
BACKGROUND: Oncostatin M (OSM) has been implicated in the pathogenesis of inflammatory bowel disease (IBD) and as a marker for nonresponsiveness to anti-tumor necrosis factor (TNF) therapy. We further unraveled the potential of OSM and related receptors as markers of diagnosis, prognosis, and therapy response in IBD. METHODS: We collected inflamed mucosal biopsies and serum from patients with Crohn disease (CD) and with ulcerative colitis: (1) newly diagnosed patients who were treatment-naïve, (2) patients initiating anti-TNF or (3) vedolizumab therapy, (4) postoperative patients with CD, and (5) multiple-affected families with IBD including unaffected first-degree relatives (FDRs). We measured the gene expression of mucosal OSM and its receptors OSMR/LIFR and co-receptor IL6ST, and the protein expression of serum OSM. Statistical significance was defined as P < 0.05. RESULTS: Newly diagnosed patients showed significantly increased mucosal OSM/OSMR compared with control patients, with the highest enrichment for OSM (fold change [FC] >17.9). Likewise, ileal OSM/OSMR were significantly upregulated in postoperative recurrent CD. Serum OSM was increased in newly diagnosed patients and postoperative patients with recurrent CD (FC ≥ 2.6). In families with IBD, higher serum levels were observed in FDRs than in control families (FC = 2.2). Furthermore, elevated colonic OSM/OSMR (but not serum OSM) were associated with the early need for biologic therapy (FC ≥ 1.9), and higher OSM was also predictive of primary nonresponse to both anti-TNF and vedolizumab therapy (FC ≥ 2.4). Immunohistochemistry highlighted mucosal OSM expression in macrophages. CONCLUSIONS: We found that OSM is a diagnostic biomarker in the tissue and serum not only of newly diagnosed patients with IBD and postoperative patients with recurrent CD but also of their FDRs. Higher colonic OSM levels are furthermore associated with poor prognosis and with primary nonresponse to biologic therapies. Therefore, OSM could guide clinical decision-making.
Authors: D P Gearing; M R Comeau; D J Friend; S D Gimpel; C J Thut; J McGourty; K K Brasher; J A King; S Gillis; B Mosley Journal: Science Date: 1992-03-13 Impact factor: 47.728
Authors: Christian Maaser; Andreas Sturm; Stephan R Vavricka; Torsten Kucharzik; Gionata Fiorino; Vito Annese; Emma Calabrese; Daniel C Baumgart; Dominik Bettenworth; Paula Borralho Nunes; Johan Burisch; Fabiana Castiglione; Rami Eliakim; Pierre Ellul; Yago González-Lama; Hannah Gordon; Steve Halligan; Konstantinos Katsanos; Uri Kopylov; Paulo G Kotze; Eduards Krustinš; Andrea Laghi; Jimmy K Limdi; Florian Rieder; Jordi Rimola; Stuart A Taylor; Damian Tolan; Patrick van Rheenen; Bram Verstockt; Jaap Stoker Journal: J Crohns Colitis Date: 2019-02-01 Impact factor: 9.071
Authors: David Kevans; Mark S Silverberg; Krzysztof Borowski; Anne Griffiths; Wei Xu; Venus Onay; Andrew D Paterson; Jo Knight; Ken Croitoru Journal: J Crohns Colitis Date: 2015-10-28 Impact factor: 9.071
Authors: Lorenzo Bertani; Matteo Fornai; Marco Fornili; Luca Antonioli; Laura Benvenuti; Gherardo Tapete; Giovanni Baiano Svizzero; Linda Ceccarelli; Maria Gloria Mumolo; Laura Baglietto; Nicola de Bortoli; Massimo Bellini; Santino Marchi; Francesco Costa; Corrado Blandizzi Journal: Aliment Pharmacol Ther Date: 2020-06-07 Impact factor: 8.171
Authors: I Arijs; K Li; G Toedter; R Quintens; L Van Lommel; K Van Steen; P Leemans; G De Hertogh; K Lemaire; M Ferrante; F Schnitzler; L Thorrez; K Ma; X-Y R Song; C Marano; G Van Assche; S Vermeire; K Geboes; F Schuit; F Baribaud; P Rutgeerts Journal: Gut Date: 2009-08-20 Impact factor: 23.059
Authors: Nathaniel R West; Ahmed N Hegazy; Benjamin M J Owens; Samuel J Bullers; Bryan Linggi; Sofia Buonocore; Margherita Coccia; Dieter Görtz; Sébastien This; Krista Stockenhuber; Johanna Pott; Matthias Friedrich; Grigory Ryzhakov; Frédéric Baribaud; Carrie Brodmerkel; Constanze Cieluch; Nahid Rahman; Gerhard Müller-Newen; Raymond J Owens; Anja A Kühl; Kevin J Maloy; Scott E Plevy; Satish Keshav; Simon P L Travis; Fiona Powrie Journal: Nat Med Date: 2017-04-03 Impact factor: 53.440
Authors: Bram Verstockt; Sare Verstockt; Jonas Dehairs; Vera Ballet; Helene Blevi; Willem-Jan Wollants; Christine Breynaert; Gert Van Assche; Séverine Vermeire; Marc Ferrante Journal: EBioMedicine Date: 2019-01-24 Impact factor: 8.143
Authors: Florence W L Tsui; Aifeng Lin; Ismail Sari; Zhenbo Zhang; Hing Wo Tsui; Robert D Inman Journal: Arthritis Res Ther Date: 2021-05-14 Impact factor: 5.156
Authors: David Martín-Hernández; Irene L Gutiérrez; Marta González-Prieto; Karina S MacDowell; Javier Robledo-Montaña; Hiram Tendilla-Beltrán; Natalia Calleja-Rodríguez; Álvaro G Bris; Cristina Ulecia-Morón; Beatriz Moreno; Javier R Caso; Borja García-Bueno; Sandra Rodrigues-Mascarenhas; Ignacio Marín-Jiménez; Juan Carlos Leza; Luis Menchén Journal: Sci Rep Date: 2022-03-08 Impact factor: 4.379